The 3 Wall Street analysts covering Kyntra Bio, Inc. hold a median 12-month price target of $39 — +476.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Kyntra Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (93): The share count has been shrinking and the company is not leaning on new borrowing.
Value (18): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Kyntra Bio, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on KYNB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +476.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 July 2026 | Oppenheimer | Initiates | Outperform | $35 |
| 9 June 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 24 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 May 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 20 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 8 Aug 2023 | B of A Securities | Downgrade | Underperform | $4.00 → $2.00 |
| 27 June 2023 | Goldman Sachs | Maintains | Sell | $16 → $2.00 |
| 27 June 2023 | Raymond James | Downgrade | Market Perform | — |
| 26 June 2023 | B of A Securities | Downgrade | Neutral | $29 → $4.00 |
| 26 June 2023 | Raymond James | Downgrade | Market Perform | — |
| 26 June 2023 | Stifel | Downgrade | Hold | $28 → $11 |
| 26 June 2023 | William Blair | Downgrade | Market Perform | — |
| 2 June 2023 | Stifel | Upgrade | Buy | — |
| 28 Feb 2023 | Cowen & Co. | Maintains | Market Perform | $15 → $25 |
| 23 Feb 2023 | Goldman Sachs | Maintains | Sell | $9.00 → $16 |
| 21 Feb 2023 | Goldman Sachs | Maintains | Sell | $9.00 → $16 |
| 31 Jan 2023 | William Blair | Upgrade | Outperform | — |
| 26 Jan 2023 | Raymond James | Upgrade | Outperform | $35 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 34% of US stocks
Cheaper than 95% of US stocks
Cheaper than 61% of US stocks
Higher than 83% of US stocks
Higher than 72% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 99% of US stocks
Higher than 99% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KYNB appears on the weeks it earns a place.
Zacks Investment Research reported that Kyntra Bio (KYNB) has the right combination of key ingredients for a likely earnings beat in its upcoming report, and advises preparing with the key expectations.
Why it matters — A KYNB watcher would care because the article suggests the company is positioned to potentially exceed earnings expectations in its next report.
The 3 Wall Street analysts covering Kyntra Bio, Inc. have a median 12-month price target of $39, with estimates ranging from $35 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Kyntra Bio, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kyntra Bio, Inc. 67 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Kyntra Bio, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (93 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +476.9% from the last close, and Ticker Nerd's factor model ranks Kyntra Bio, Inc. 67 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kyntra Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KYNB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $43 over the next 12 months.
Kyntra Bio, Inc. returned -1.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs, with a primary focus on oncology and rare diseases.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: Should You Buy?". Zacks Investment Research reported that Kyntra Bio (KYNB) has the right combination of key ingredients for a likely earnings beat in its upcoming report, and advises preparing with the key expectations.
Kyntra Bio, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics for serious unmet medical needs, with a primary focus on oncology and rare diseases. Headquartered in San Francisco, California, and incorporated in 1993, the company today centers its efforts on targeted therapies for cancer and anemia-related conditions. A key program is FG-3246, a first-in-class antibody-drug conjugate targeting CD46, being evaluated for metastatic castration-resistant prostate cancer, alongside FG-3180, a related PET imaging biomarker designed to visualize CD46-positive tumors and support patient selection. Kyntra Bio also develops roxadustat, an oral small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase, used for the treatment of anemia in chronic kidney disease and investigated in myelodysplastic syndromes. Through internal R&D and collaboration agreements with partners such as Astellas Pharma and AstraZeneca, Kyntra Bio occupies a specialized role in the healthcare sector, aiming to provide differentiated, mechanism-based therapies across global markets.
CEO Mr. Thane Wettig · 34 employees · United States · https://www.kyntrabio.com